Cefaclor in the treatment of otitis media with effusion.
A randomized clinical trial in which 91 children with chronic OME participated was performed. Cefaclor 20 mg/kg body weight b.i.d. was given to the treated group (n = 46) during 10 days preceding the day appointed for surgery. The control group (n = 45) remained untreated. On the day scheduled for surgery 24 (52%) of the treated cases had healed, compared to 5 (11%) of the untreated cases, a significant difference (p less than 0.001). The long term effects showed that in the treated group 18 of the 24 primarily healed remained unoperated at a median follow-up period of 20 months. In the untreated group two of the five that originally resolved later relapsed and were subjected to surgery.
D002433:Cefaclor / Q000627:therapeutic use*; D002506:Cephalexin / Q000031:analogs & derivatives*; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D010034:Otitis Media with Effusion / Q000188:drug therapy*; D012008:Recurrence
D002433:Cefaclor; D002506:Cephalexin